FDA approves anti-obesity drug as first sleep apnea medication - Washington Examiner
Zepbound, approved for treating obstructive sleep apnea (OSA) in obese patients, is the first medication to significantly improve moderate-to-severe OSA and aid long-term weight loss. OSA, underdiagnosed and linked to obesity and Type 2 diabetes, involves airway blockage during sleep causing apneic episodes. Clinical trials showed Zepbound eliminated OSA symptoms in 43% and 51% of patients.
Highlighted Terms
Related News
Zepbound, approved for treating obstructive sleep apnea (OSA) in obese patients, is the first medication to significantly improve moderate-to-severe OSA and aid long-term weight loss. OSA, underdiagnosed and linked to obesity and Type 2 diabetes, involves airway blockage during sleep causing apneic episodes. Clinical trials showed Zepbound eliminated OSA symptoms in 43% and 51% of patients.